Compared to that in NBM CD34+ cells, the Spred2 expression was lower notably in CML CD34+ cells (Fig. 2A), which was consistent with the impaired differentiation ability of these cells. This evidence concerns the gene SPRED2 and chronic myelogenous leukemia, BCR-ABL1 positive.